会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • IDENTIFICATION OF COMMON CHEMICAL ACTIVITY THROUGH COMPARISON OF SUBSTRUCTURAL FRAGMENTS
    • 通过比较结构化片段来识别共同化学活性
    • WO1997014106A1
    • 1997-04-17
    • PCT/US1996016196
    • 1996-10-10
    • TERRAPIN TECHNOLOGIES, INC.
    • TERRAPIN TECHNOLOGIES, INC.VILLAR, Hugo, O.BONE, Richard, G., A.
    • G06F17/30
    • B01J19/00C07K1/00G06F19/704G06F19/709
    • A process for preparing a database of molecule fragments contained by a molecule, the process including the steps of (1) selecting a molecule comprising molecule fragments; (2) identifying substantially all molecule fragments within the molecule; (3) counting the occurrence of each unique molecule fragment identified in step 2; and (4) storing in a computer-readable storage medium information correlating molecule fragment count with molecule fragment identity. The invention also relates to a computer-implemented process for identifying a molecule likely to have a desired trait, the process including the steps of (1) selecting a test molecule comprising molecule fragments; (2) identifying substantially all test molecule fragments within the molecule; (3) counting the occurrence of each unique test molecule fragment identified in step 2; (4) comparing test molecule fragment counts from step 3 with fragment counts for identical fragments from a plurality of molecules having known activity; and (5) presenting the results of the comparing step as an output. The invention also includes a data processing system implementing these processes and computer-readable media having recorded thereon databases containing standardized representations of substantially all fragments of one or more molecules.
    • 一种制备分子含有的分子片段的数据库的方法,所述方法包括以下步骤:(1)选择包含分子片段的分子; (2)基本上确定分子内的所有分子片段; (3)计算步骤2中鉴定的每个独特分子片段的出现; 和(4)在计算机可读存储介质中存储相关分子片段计数与分子片段同一性的信息。 本发明还涉及用于鉴定可能具有所需性状的分子的计算机实施方法,所述方法包括以下步骤:(1)选择包含分子片段的测试分子; (2)确定分子内基本上所有测试分子片段; (3)计算步骤2中鉴定的每个独特的测试分子片段的发生情况; (4)将来自步骤3的测试分子片段计数与来自具有已知活性的多个分子的相同片段的片段计数进行比较; 和(5)将比较步骤的结果呈现为输出。 本发明还包括实现这些过程的数据处理系统和其上记录有包含一个或多个分子的基本上所有片段的标准化表示的数据库的计算机可读介质。
    • 6. 发明申请
    • GLUTATHIONE ANALOGS AND PARALOG PANELS COMPRISING GLUTATHIONE MIMICS
    • GLUTATHIONE模拟和包含GLUTATHIONE MIMICS的对话面板
    • WO1995008563A1
    • 1995-03-30
    • PCT/US1994010797
    • 1994-09-23
    • TERRAPIN TECHNOLOGIES, INC.
    • TERRAPIN TECHNOLOGIES, INC.KAUVAR, Lawrence, M.LYTTLE, Matthew, H.
    • C07K05/037
    • A61K38/06C07K5/0215C12N9/1088G01N30/02G01N33/573G01N33/57496G01N2333/91177B01D15/3804B01D15/422
    • A compound of formula (1) and the alkyl-type (1-10C), alkenyl-type (1-10C), and arylalkyl-type (7-12C) esters, amides and mixed ester/amides thereof; wherein Z is selected from the group consisting of S, O, and C; n is 1, 2 or 3; wherein when Z is O or S and n is 1, X is a mono- or disubstituted or unsubstituted hydrocarbyl (1-20C) moiety optionally containing 1 or 2 nonadjacent heteroatoms (O, S or N), and wherein said substitution is selected from the group consisting of halo, -NO, -NO2, -NR2, OR, and SR, wherein each R is independently H or lower alkyl (1-4C); wherein when Z is S and n is 2, one X is as above defined and the other X is lower alkyl (1-4C); and wherein when Z is C and n is 3, one X is as above defined and the other two X are independently H or lower alkyl (1-4C); Y-CO is selected from the group consisting of gamma -Glu, beta -Asp, Glu, Asp, gamma Glu-Gly, beta -Asp-Gly, Glu-Gly, and Asp-Gly, and AAC is an amino acid coupled through a peptide bond to the remainder of the compound of formula (1), are useful as affinity ligands, elution reagents, solution inhibitors, diagnostic reagents and therapeutics. These compounds and analogous tripeptide glutathione analogs can be used as members of panels to obtain specific characteristic profiles for various glutathione-S-transferases.
    • 式(1)的化合物和烷基型(1-10C),链烯基(1-10C)和芳基烷基(7-12C)酯,酰胺和其混合酯/酰胺; 其中Z选自S,O和C; n为1,2或3; 其中当Z为O或S且n为1时,X为任选含有1或2个不相邻杂原子(O,S或N)的单取代或未取代的烃基(1-20C)部分,并且其中所述取代选自 由卤素,-NO,-NO 2,-NR 2,OR和SR组成的基团,其中每个R独立地为H或低级烷基(1-4C); 其中当Z为S且n为2时,一个X如上定义,另一个X为低级烷基(1-4C); 并且其中当Z为C且n为3时,一个X如上定义,另外两个X独立地为H或低级烷基(1-4C); Y-CO选自γ-Glu,β-Asp,Glu,Asp,γ-Glu-Gly,β-Asp-Gly,Glu-Gly和Asp-Gly,AAC是通过 与式(1)化合物的其余部分的肽键可用作亲和配体,洗脱试剂,溶液抑制剂,诊断试剂和治疗剂。 这些化合物和类似的三肽谷胱甘肽类似物可用作面板的成员以获得各种谷胱甘肽-S-转移酶的特定特征。
    • 7. 发明申请
    • DETERMINATION OF CONCENTRATION BY AFFINITY TITRATION AND COMPETITIVE DISPLACEMENT IN DRUG DELIVERY
    • 通过精神量化和药物递送中的竞争性位移来确定浓度
    • WO1994023298A1
    • 1994-10-13
    • PCT/US1994003490
    • 1994-03-30
    • TERRAPIN TECHNOLOGIES, INC.
    • TERRAPIN TECHNOLOGIES, INC.KAUVAR, Lawrence, M.
    • G01N33/543
    • G01N33/54306A61K47/6817G01N33/53
    • A method for determining the amount of analyte in a sample utilizes a series of test regions with systematically varied, preferably monotonically increasing, affinity for a specific binding partner for an analyte or for the analyte itself. By determining the portion of test regions which are capable of binding specific binding partner in competition with the analyte in the sample, or which bind the analyte, the amount of analyte may be estimated. Thus, titration of affinity replaces titration of concentration, allowing assays to be performed without the need for serial dilution steps. Alternatively, advantage is taken of competition of various ligands for components of complexes to regulate the release of desired components from the complexes. In one embodiment, clearance of small moieties can be delayed by combining them with size-enhancing agents which can be released or dissociated on cue by action of a releasing agent. In other embodiments, a target itself is a successful competitor in releasing the active form of the moiety from the complex.
    • 用于确定样品中分析物的量的方法利用一系列测试区域,其对于分析物或分析物本身的特异性结合配偶体系统地改变,优选单调递增的亲和力。 通过确定能够结合特异性结合配偶体与样品中分析物竞争或测量结合分析物的部分测试区域,可以估计分析物的量。 因此,亲和力的滴定取代浓度的滴定,允许进行测定而不需要连续稀释步骤。 或者,优点是各种配体竞争复合物的组分以调节所需组分从配合物的释放。 在一个实施方案中,小部分的清除可以通过将它们与尺寸增强剂组合来延迟,所述尺寸增强剂可以通过释放剂的作用在提示上释放或解离。 在其它实施方案中,靶自身是从复合物释放部分活性形式的成功竞争者。